Top Medical News
Jairia Dela Cruz, an hour ago
Use of proton pump inhibitors and histamine‐2 receptor antagonists appears to reduce the risk of developing oesophageal carcinoma in patients with Barret’s oesophagus, according to a study.
Roshini Claire Anthony, 20 hours ago

Administering sodium thiosulfate 6 hours after cisplatin therapy almost halved the incidence of hearing loss in children with hepatoblastoma, according to results of the phase III SIOPEL 6* trial.

Stephen Padilla, 23 hours ago
Community hospitals conducting hemithyroidectomy in Singapore achieve satisfactory disease control and excellent survival for minimally invasive follicular thyroid carcinoma (MIFTC), according to a recent study, adding that total thyroidectomy should be reserved for widely invasive (WI)FTC or aggressive tumours with nodal or distant metastasis.
Catumaxomab therapy in addition to systemic chemotherapy is a feasible and tolerable treatment for peritoneal carcinomatosis in patients with gastric cancer, a phase II trial has shown.
In large cT2 renal masses, robot-assisted partial nephrectomy appears to be a safe approach with acceptable outcomes, a recent study has shown.
Jairia Dela Cruz, 2 days ago
Use of zoledronic acid for 2 years appears to be effective against cancer treatment-induced bone loss in premenopausal women with breast cancer, with bone mass density values maintained for up to 3 years after cessation of treatment, according to the results of the placebo-controlled ProBone II trial.
2 days ago
In survivors of uveal melanoma, worry about recurrent disease (WREC) and post-treatment symptoms appear to contribute to long-term anxiety and depression, according to a recent study.
Special Reports
21 May 2018
At the recent American Society of Haematology Annual Meeting 2017, Professor François-Xavier Mahon reviewed recent studies related to tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukaemia (CML) who have achieved sustained deep molecular response (DMR).
01 May 2018
ABSTRAL - Fentanyl citrate 100 mcg, 200 mcg and 400 mcg SL tab - A. Menarini
Rachel Soon, 28 Feb 2018

Recent developments on CDK 4/6 trials in patients with oestrogen receptor-positive metastatic breast cancers (ER+ MBC) were reviewed at ESMO and ASCO 2017.

29 Jan 2018

Role of comprehensive genomic profiling in personalized treatment

22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
04 Dec 2017
Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.
Dr Joslyn Ngu, 04 Dec 2017

Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.

Conference Reports
Elaine Soliven, 11 Jul 2018

Adding bevacizumab to platinum-based chemotherapy significantly improves progression-free survival (PFS) in patients with recurrent ovarian cancer who were previously treated with first-line bevacizumab, according to the MITO16B - MaNGO OV2B - ENGOT OV17* study presented at ASCO 2018.

Audrey Abella, 06 Jul 2018
The addition of the EGFR inhibitor nimotuzumab to a chemoradiotherapy (CRT) regimen using cisplatin improved progression-free survival (PFS) and disease-free survival (DFS) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) compared with CRT alone, according to data from a phase III trial presented at ASCO 2018.
Roshini Claire Anthony, 04 Jul 2018

Patients with metastatic clear-cell renal cell carcinoma (mRCC) who received sunitinib appeared to have comparable overall survival (OS) with those who received sunitinib after undergoing cytoreductive nephrectomy, according to the phase III CARMENA* trial.

Pearl Toh, 03 Jul 2018
Matching targeted therapy to genetic alterations in the tumour improved response rate and long-term survival in patients with advanced cancer who underwent molecular profiling compared with patients who were unmatched to therapy, highlighting the role of molecular testing in precision medicine, the IMPACT* study shows.
Audrey Abella, 03 Jul 2018
The antibody-drug conjugate enfortumab vedotin (EV) demonstrated a promising overall response rate (ORR) in patients with metastatic urothelial cancer (mUC), including those who had liver metastases and prior treatment with checkpoint inhibitors, according to the phase 1 data of the EV-101* trial presented at ASCO 2018.
Pearl Toh, 02 Jul 2018
Adding atezolizumab to a combination therapy of bevacizumab plus carboplatin and paclitaxel (CP) significantly improves progression-free survival (PFS) and overall survival (OS) in chemotherapy-naïve patients with metastatic nonsquamous non-small–cell lung cancer (NSCLC), irrespective of PD-L1 expression levels and EGFR or ALK alteration status, according to the IMpower150* trial presented at ASCO 2018.
Pearl Toh, 29 Jun 2018
Treatment with adjuvant trastuzumab for 6 months was noninferior to 12 months — the current standard treatment duration for HER2-positive early-stage breast cancer — in terms of disease-free survival (DFS), according to the PERSEPHONE* trial presented in ASCO 2018.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download